Salivary Melatonin Profile: At-Home and Finger-Prick Options Explained

A salivary melatonin profile is a series of timed saliva samples, usually 6 to 10 collections over 5 to 7 hours in dim light, used to estimate dim-light melatonin onset (DLMO): the clock time when melatonin begins its nightly rise. It is distinct from a single serum melatonin draw (a snapshot with no timing information), a urinary 6-sulfatoxymelatonin (aMT6s) test (a total-output number with no timing information), and a finger-prick dried blood spot (DBS) card (a timing method that measures total rather than free melatonin). In sleep and circadian medicine, DLMO measured by serial saliva sampling is the method used in clinical practice guidelines to time the circadian pacemaker; a single blood or urine sample cannot substitute for it because neither captures when the rise happens.

This article covers what the test measures, how to collect it at home without invalidating the result, what a finger-prick alternative can and cannot tell you, and where the underlying evidence is strong versus where specific numbers in circulating claims about this test need direct verification before they are used clinically.

What a Salivary Melatonin Profile Actually Measures

The pineal gland secretes melatonin under control of the suprachiasmatic nucleus (SCN), which receives light information through melanopsin-containing retinal ganglion cells. Melatonin diffuses passively into saliva, so salivary concentration tracks the free (unbound) fraction of plasma melatonin with a short physiological lag. This general mechanism is well established in circadian biology and is the basis for using saliva instead of blood in outpatient and at-home settings.

A profile captures three things a single measurement cannot: the clock time of onset (DLMO), the peak concentration reached overnight, and the rate of decline toward morning. DLMO is operationally defined in the research literature as the time when salivary melatonin first rises above and stays above a fixed threshold, commonly cited as 3 to 4 pg/mL, though the exact threshold varies by assay and by laboratory, and that variability itself is a reason to interpret an absolute cutoff cautiously rather than as a fixed biological constant.

The Endocrine Society and the American Academy of Sleep Medicine (AASM) both address circadian rhythm sleep-wake disorders in published clinical practice guidance, and strategically timed melatonin is recommended for delayed sleep-wake phase disorder (DSWPD) in that guidance. The exact wording and recommendation strength of these guidelines should be checked directly against the current published version before being quoted in patient materials, since guideline language and recommendation grades are periodically revised.

What Counts as a Normal Range, and Why That's Harder Than It Sounds

Published circadian research generally describes a population DLMO window in the evening hours, with individual variation related to age, chronotype, and light history. Overnight peak concentrations are commonly reported as higher in younger adults and lower in older adults, consistent with a broader literature on age-related decline in pineal melatonin output. However, the specific numeric ranges attached to age bands (for example, precise pg/mL cutoffs by decade) vary meaningfully between reference laboratories and assay platforms, and a table of exact numbers should not be treated as a universal clinical standard without confirming which assay and reference population it came from. Any reader comparing a personal result to a printed range should ask the ordering lab which reference population and assay their range is based on, not assume it matches numbers seen elsewhere.

What is established: DLMO timing relative to a person's desired or habitual sleep time is more clinically informative than the absolute peak concentration. A person whose onset occurs several hours later than their required wake-sleep window has a physiological explanation for chronic sleep-onset difficulty that a single low-concentration blood test would miss entirely.

What is plausible but not settled for a general audience: associations between DLMO timing or amplitude and downstream metabolic or mood outcomes appear in some observational cohorts. These associations do not establish that correcting DLMO timing changes those outcomes, and any specific effect size attached to such a claim needs to be checked against the primary study before it is repeated as fact.

What is not established from the material available here: a single validated "optimal" numeric target that applies across labs, ages, and assay methods. Treat any single-number "ideal DLMO" or "ideal peak" claim as a working convention of a particular lab, not a universal clinical threshold.

Collecting the Sample at Home Without Invalidating It

Protocol adherence, not assay sensitivity, is the most common reason a home salivary melatonin profile becomes uninterpretable.

Light conditions. The collection environment needs to stay below roughly 10 lux throughout sampling, typically starting several hours before the person's habitual sleep time. Ordinary room lighting and unfiltered screens are well above this threshold and can suppress the very signal the test is trying to measure. Dim red light at low intensity does not activate the melanopsin pathway the way blue-enriched light does, which is why some protocols permit red light but not white or blue-enriched light during collection.

Timing anchored to the person, not the clock. A common protocol error is starting collection at a fixed clock time regardless of when the person actually sleeps. Circadian research guidance recommends anchoring the collection window to the individual's habitual sleep onset rather than a generic evening schedule; a night-shift worker who sleeps at 4 a.m. needs a collection window shifted accordingly, not one built around a typical 10 p.m. bedtime.

Sample handling. Food, non-water beverages, and tooth brushing in the 30 minutes before a sample can contaminate the assay. Samples generally need to be frozen soon after collection or refrigerated and shipped promptly; degradation during shipping is a recognized source of falsely low readings. Ask the specific lab for its own validated stability window rather than assuming a generic number applies.

Recent exogenous melatonin use. Melatonin supplements taken in the days before testing will raise concentrations and can shift the apparent DLMO artificially earlier. Anyone using melatonin regularly should discuss with the ordering clinician whether and how long to pause it before testing, since stopping a sleep aid without a plan can itself worsen short-term sleep.

Decision Framework: Choosing a Method and Trusting the Result

This framework is designed for a reader deciding between at-home saliva collection, a finger-prick DBS kit, urinary aMT6s, or a single blood draw, and for judging whether a completed result is trustworthy enough to act on.

Step 1: What question are you actually asking?

• If the question is "when does my circadian clock turn on," you need timing information. Only a multi-sample saliva or DBS profile answers this. A single blood draw or a first-morning urine test cannot, regardless of how the result is marketed.
• If the question is "roughly how much melatonin am I making overall," a single urinary aMT6s sample is cheaper and lower-burden, but it tells you nothing about timing and cannot diagnose a phase disorder like DSWPD.

Step 2: Can you actually complete the protocol?

• Multi-sample saliva collection requires 5 to 7 hours of controlled dim light and cannot be done casually around a normal evening. If a strict dim-light room is not realistic in your home, a result from that attempt should be treated as unreliable rather than diagnostic.
• DBS finger-prick cards are lower burden and may be preferable for people who cannot produce adequate saliva volume, including some older adults on medications that reduce saliva production, but they still require correct timing of each card relative to habitual sleep.

Step 3: What medications or exposures do you need to disclose before ordering?

• Beta-blockers, NSAIDs, and recent caffeine intake are all reported in the circadian physiology literature to blunt or shift nocturnal melatonin secretion. Any of these taken close to the test should be disclosed to the ordering clinician, because a "low" or "delayed" result caused by a medication is not the same clinical finding as an intrinsic circadian disorder.
• Any melatonin supplement use in the days before testing should be disclosed and, when appropriate, paused under clinical guidance, because it can produce an artifactually early or elevated result.

Step 4: Interpreting a completed result.

• A result showing DLMO occurring much later than desired sleep time, in the context of chronic difficulty falling asleep at a normal hour and difficulty waking early, is consistent with DSWPD and supports a conversation with a sleep clinician about strategically timed melatonin and light therapy, not self-directed dosing.
• A blunted peak alone, without confirmed timing delay, is not sufficient to diagnose a circadian disorder and should first be checked against medication use, recent light exposure, and sample handling before being treated as a primary finding.
• A single low or high number without the surrounding curve is not interpretable. If a lab reports only one concentration rather than the full timed series, ask whether that is actually the product ordered.

Step 5: When to involve a clinician rather than interpret alone.

• Any pattern that includes severe insomnia, excessive daytime sleepiness affecting driving or safety, mood symptoms, or a child with a suspected circadian disorder warrants clinician involvement rather than self-directed interpretation of an at-home kit. Melatonin dosing and light-therapy timing based on DLMO should be set by a clinician familiar with circadian medicine, not chosen independently from a home report.

Finger-Prick and Dried Blood Spot Testing

Dried blood spot (DBS) cards are used as an alternative collection method for melatonin timing studies, particularly for people who have difficulty producing enough saliva. The general validation literature on DBS methods in circadian research reports strong agreement with plasma sampling, but the exact correlation coefficients circulating in secondary summaries of this literature need to be checked against the specific primary study before being cited as an exact number; do not treat any single precise correlation figure here as confirmed without that check.

The main conceptual difference between DBS and saliva is that DBS measures total melatonin (bound plus free), while saliva measures only the free fraction. In practice this distinction is not expected to move the DLMO estimate by more than a modest amount, but the precise magnitude of that difference should be sourced to the specific validation study rather than assumed.

Saliva, DBS, urine, and serum compared

For any question that depends on knowing when the circadian clock turns on, a single blood or urine sample is the wrong test regardless of cost or convenience.

Conditions Where Timing Information Changes Management

Delayed sleep-wake phase disorder (DSWPD). DSWPD is characterized by an inability to fall asleep and wake at conventional times, with the underlying circadian clock timed later than the person's required schedule. Confirming a delayed DLMO distinguishes DSWPD from psychophysiological insomnia, where the underlying clock timing is not delayed. Guideline bodies addressing circadian rhythm sleep-wake disorders support strategically timed melatonin for DSWPD; the exact dose, timing formula, and phase-advance rate quoted in various secondary sources vary and should be confirmed against the current primary guideline and prescribing clinician rather than applied as a fixed self-dosing rule. Mistimed melatonin can shift the clock in the wrong direction, which is one reason dosing should be set by a clinician using the actual DLMO rather than guessed from symptoms alone.

Shift-work disorder and circadian misalignment. The World Health Organization's International Agency for Research on Cancer has classified night shift work involving circadian disruption as a probable human carcinogen (Group 2A), a classification grounded in the broader body of evidence on circadian disruption rather than a single melatonin measurement. This classification should be verified against current IARC/WHO materials before being cited, as classifications and framing are periodically updated. A salivary or DBS profile can quantify the degree of misalignment between a shift worker's clock and their required schedule, which supports more targeted timing of light exposure and melatonin than a symptom-based approach alone, though the profile itself does not treat the disorder.

Menopause-related sleep disruption. Some cross-sectional research reports lower melatonin metabolite output in perimenopausal women compared with premenopausal women, but the specific percentage figures attached to this claim in various secondary summaries should be verified against the original cohort study before being used clinically. The clinically useful distinction this test can support is separating melatonin-related sleep-onset difficulty from hot-flash-driven nighttime arousal, which point toward different treatment approaches (melatonin versus menopause-focused therapy), a distinction best made with a clinician reviewing the full sleep and symptom picture, not the lab value alone.

Autism spectrum disorder (ASD). Melatonin-related sleep difficulty is common in children with ASD, and prolonged-release melatonin has trial evidence supporting its use for sleep-onset difficulty in this population as an off-label or, depending on formulation and country, approved pediatric indication; prescribing details and current approval status should be verified against the current product label, since formulations and approvals differ by region. Baseline profiling, where used, is intended to help distinguish a genuine melatonin deficit from a purely behavioral sleep-onset association problem, which point toward different first-line interventions.

Factors That Suppress or Shift Results

Several exposures are reported in the circadian physiology literature to reduce or delay nocturnal melatonin secretion, which can make a result look pathological when the cause is external rather than an intrinsic pineal or circadian problem:

• Beta-blockers, through beta-adrenergic blockade of the pineal signaling pathway that drives melatonin synthesis
• NSAIDs, through cyclooxygenase inhibition affecting pineal signaling
• Caffeine consumed in the evening
• Bright or blue-enriched light in the hours before and during collection
• Recent exogenous melatonin use, which artificially raises concentrations and shifts apparent onset earlier

The exact magnitude of suppression or shift reported for each of these (for example, a specific percentage reduction or a specific number of minutes of delay) varies across the primary studies that report them and should be confirmed against the specific paper before being presented as a precise, universal figure. The safe clinical takeaway is qualitative: disclose all of these to the ordering clinician and the lab, because any one of them can explain an abnormal-looking profile without indicating an intrinsic circadian disorder.

Selecting a Laboratory

A few practical checks distinguish a lab whose result is likely to be trustworthy:

• Assay sensitivity. The lab should be able to reliably detect concentrations well below typical evening levels, since daytime and pre-onset concentrations are low and an insensitive assay cannot distinguish a true low reading from assay noise.
• Documented stability data. A credible lab publishes or can provide, on request, its own validated data on how long samples remain stable frozen versus refrigerated, rather than relying on generic industry figures.
• CLIA certification. In the United States, clinical laboratory testing must be performed in a CLIA-certified facility. Patients ordering a direct-to-consumer kit should confirm the processing lab's CLIA status. A general reference for CLIA categorization is available from the FDA. FDA CLIA categorizations (check for current status, as regulatory pages are updated over time).

What This Test Cannot Tell You

A salivary or DBS melatonin profile estimates circadian timing under the specific conditions of that one collection night. It does not diagnose depression, does not rule out other sleep disorders such as obstructive sleep apnea, and does not by itself justify a specific melatonin dose without clinical interpretation. Anyone with excessive daytime sleepiness affecting driving safety, suspected sleep apnea (snoring, witnessed pauses in breathing, morning headaches), or a child with a complex sleep and behavioral picture should be evaluated clinically rather than relying on an at-home profile alone.